Bicalutamide

SKU: orb1310668

Description

Bicalutamide is a nonsteroidal antiandrogen that acts by competitively inhibiting androgen receptor binding. It is widely used in research to study androgen receptor signaling in prostate cancer models, both in vitro and in vivo.

Research Area

Cell Biology, Metabolism Research, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 90357-06-5
• MW: 430.37
• Purity: 99.97% (May vary between batches)
• Formula: C₁₈H₁₄F₄N₂O₄S
• SMILES: CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F
• Target: Androgen Receptor,Autophagy
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.65 mM);Ethanol:4.31 mg/mL (10.01 mM);DMSO:250 mg/mL (580.9 mM)

Bioactivity

• Target IC50:
  Androgen receptor:0.16 μM
• In Vivo:
  Single bicalutamide reduces tumor growth by 79%, at defined submaximal doses. The ridaforolimus-bicalutamide combination exhibits improved and potent antitumor activity, almost completely abrogating tumor growth. The combination is also well tolerated, as evidenced by no significant changes in body weight over the course of treatment. Plasma PSA levels are again tightly linked to tumor growth in the combination-treated mice.
  Read more...
• Cell Research:
  Exponentially growing C4-2 cells are plated into two 96-well plates and incubated overnight at 37 C. Twenty-four hours later one plate is aspirated and stored at -80 C and the other treated with 10-fold serial concentrations of ridaforolimus (1000 nM to 0.0001 nM) or vehicle (ethanol). Following 72 hours culture at 37 C, the plates are assessed simultaneously for cell growth using the Cy qUANT Cell Proliferation Assay kit. Bicalutamide and Ridaforolimus combination proliferation assays are performed similarly except cell growth is determined as the change in cell number between vehicle control and compound treated cells after 72 hours in culture.(Only for Reference)
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

cancer, Bicalutamide, Autophagy, anti-androgen, Androgen Receptor, AndrogenReceptor, androgen, castration-resistant, non-steroidal, inhibit, ICI 176334, ICI176334, ICI-176334, Inhibitor, receptor, prostate, prostate cancer

Compound Identifiers

PubChem CID

2375